Peringatan Keamanan

No cases of significant accidental or intentional overdose have been reported. Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.

Rocuronium

DB00728

small molecule approved

Deskripsi

Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a ?-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.

Struktur Molekul 2D

Berat 529.7742
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.
Volume Distribusi * 0.3 L/kg [3 to <12 mos] * 0.26 L/kg [1 to <3 yrs] * 0.21 L/kg [3 to <8 yrs]
Klirens (Clearance) * 0.25 L/kg/hr [Adults (Ages 27 to 58 years)] * 0.21 L/kg/hr [Geriatrics (>=65 yrs)] * 0.16 L/kg/hr [Normal ewnal and hepatice function] * 0.13 L/kg/hr [Renal transplant patients] * 0.13 L/kg/hr [Hepatic dysfunction patients] * 0.35 +/- 0.08 L/kg/hr [Pediatric Patients 3 to <12 mos] * 0.32 +/- 0.07 L/kg/hr [Pediatric Patients 1 to 3 yrs] * 0.44 +/- 0.16 L/kg/hr [Pediatric Patients 3 to 8 yrs]

Absorpsi

Poorly absorbed from the GI tract.

Metabolisme

Rocuronium is metabolized to a less active metabolite, 17-desacetyl-rocuronium, and is eliminated primarily by the liver.

Rute Eliminasi

Studies of distribution, metabolism, and excretion in cats and dogs indicate that rocuronium is eliminated primarily by the liver.

Interaksi Obat

1256 Data
Buprenorphine Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.
Hydrocodone Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.
Magnesium sulfate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Rocuronium may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.
Mirtazapine Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.
Orphenadrine Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.
Pramipexole Rocuronium may increase the sedative activities of Pramipexole.
Ropinirole Rocuronium may increase the sedative activities of Ropinirole.
Rotigotine Rocuronium may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Rocuronium.
Sodium oxybate The risk or severity of CNS depression can be increased when Rocuronium is combined with Sodium oxybate.
Suvorexant Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.
Thalidomide Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Capreomycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Capreomycin.
Cyclosporine The therapeutic efficacy of Rocuronium can be increased when used in combination with Cyclosporine.
Doxycycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Doxycycline.
Lymecycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Lymecycline.
Framycetin The therapeutic efficacy of Rocuronium can be increased when used in combination with Framycetin.
Clomocycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Clomocycline.
Quinine The therapeutic efficacy of Rocuronium can be increased when used in combination with Quinine.
Vancomycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Vancomycin.
Tigecycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Tigecycline.
Oxytetracycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Oxytetracycline.
Chloroquine The therapeutic efficacy of Rocuronium can be increased when used in combination with Chloroquine.
Demeclocycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Demeclocycline.
Mecamylamine The therapeutic efficacy of Rocuronium can be increased when used in combination with Mecamylamine.
Tobramycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Tobramycin.
Tetracycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Tetracycline.
Gentamicin The therapeutic efficacy of Rocuronium can be increased when used in combination with Gentamicin.
Etacrynic acid The therapeutic efficacy of Rocuronium can be increased when used in combination with Etacrynic acid.
Quinidine The therapeutic efficacy of Rocuronium can be increased when used in combination with Quinidine.
Metacycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Metacycline.
Netilmicin The therapeutic efficacy of Rocuronium can be increased when used in combination with Netilmicin.
Neomycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Neomycin.
Streptomycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Streptomycin.
Colistimethate The therapeutic efficacy of Rocuronium can be increased when used in combination with Colistimethate.
Kanamycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Kanamycin.
Rolitetracycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Rolitetracycline.
Magnesium oxide The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium oxide.
Magnesium cation The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium cation.
Paromomycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Paromomycin.
Lincomycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Lincomycin.
Ribostamycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Ribostamycin.
Geneticin The therapeutic efficacy of Rocuronium can be increased when used in combination with Geneticin.
Apramycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Apramycin.
Gentamicin C1a The therapeutic efficacy of Rocuronium can be increased when used in combination with Gentamicin C1a.
Neamine The therapeutic efficacy of Rocuronium can be increased when used in combination with Neamine.
Arbekacin The therapeutic efficacy of Rocuronium can be increased when used in combination with Arbekacin.
Viomycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Viomycin.
Puromycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Puromycin.
Magnesium hydroxide The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium hydroxide.
Magnesium trisilicate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium trisilicate.
Magnesium chloride The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium chloride.
Magnesium acetate tetrahydrate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium acetate tetrahydrate.
Magnesium carbonate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium carbonate.
Magnesium citrate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium citrate.
Magnesium glycinate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium glycinate.
Magnesium Aluminum Silicate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium Aluminum Silicate.
Dihydrostreptomycin The therapeutic efficacy of Rocuronium can be increased when used in combination with Dihydrostreptomycin.
Hygromycin B The therapeutic efficacy of Rocuronium can be increased when used in combination with Hygromycin B.
Sisomicin The therapeutic efficacy of Rocuronium can be increased when used in combination with Sisomicin.
Plazomicin The therapeutic efficacy of Rocuronium can be increased when used in combination with Plazomicin.
Magnesium silicate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium silicate.
Penimepicycline The therapeutic efficacy of Rocuronium can be increased when used in combination with Penimepicycline.
Magnesium aspartate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium aspartate.
Isepamicin The therapeutic efficacy of Rocuronium can be increased when used in combination with Isepamicin.
Magnesium gluconate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium gluconate.
Magnesium orotate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium orotate.
Magnesium phosphate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium phosphate.
Magnesium acetate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium acetate.
Procainamide The therapeutic efficacy of Rocuronium can be increased when used in combination with Procainamide.
Dantrolene The therapeutic efficacy of Rocuronium can be increased when used in combination with Dantrolene.
Piperacillin The therapeutic efficacy of Rocuronium can be increased when used in combination with Piperacillin.
Magnesium stearate The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium stearate.
Colistin The therapeutic efficacy of Rocuronium can be increased when used in combination with Colistin.
Aclidinium The risk or severity of adverse effects can be increased when Rocuronium is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Rocuronium.
Mirabegron The risk or severity of urinary retention can be increased when Rocuronium is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Rocuronium is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Rocuronium.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Rocuronium.
Tiotropium The risk or severity of adverse effects can be increased when Rocuronium is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Rocuronium is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Rocuronium is combined with Umeclidinium.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Rocuronium.
Glycopyrronium The risk or severity of adverse effects can be increased when Rocuronium is combined with Glycopyrronium.
Spironolactone Spironolactone may increase the neuromuscular blocking activities of Rocuronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Rocuronium is combined with Botulinum toxin type A.
Glucagon Rocuronium may increase the gastrointestinal motility reducing activities of Glucagon.

Target Protein

Neuronal acetylcholine receptor subunit alpha-2 CHRNA2
Muscarinic acetylcholine receptor M2 CHRM2
5-hydroxytryptamine receptor 3A HTR3A

Referensi & Sumber

Synthesis reference: Eliezer Adar, David Sondack, Oded Friedman, Iosef Manascu, Tamir Fizitzki, Boris Freger, Oded Arad, Alexander Weisman, Joseph Kaspi, "Processes for the preparation of rocuronium bromide and intermediates thereof." U.S. Patent US20050159398, issued July 21, 2005.
Artikel (PubMed)
  • PMID: 1551294
    Agoston S, Vandenbrom RH, Wierda JM: Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet. 1992 Feb;22(2):94-115.
  • PMID: 8877248
    Khuenl-Brady KS, Sparr H: Clinical pharmacokinetics of rocuronium bromide. Clin Pharmacokinet. 1996 Sep;31(3):174-83.
  • PMID: 9424684
    Alvarez-Gomez JA: Rocuronium. Rev Esp Anestesiol Reanim. 1997 Oct;44(8):310-4.
  • PMID: 8122487
    Wicks TC: The pharmacology of rocuronium bromide (ORG 9426). AANA J. 1994 Feb;62(1):33-8.
  • PMID: 11434449
    Sparr HJ, Beaufort TM, Fuchs-Buder T: Newer neuromuscular blocking agents: how do they compare with established agents? Drugs. 2001;61(7):919-42.
  • PMID: 18603747
    Hemmerling TM, Russo G, Bracco D: Neuromuscular blockade in cardiac surgery: an update for clinicians. Ann Card Anaesth. 2008 Jul-Dec;11(2):80-90.

Contoh Produk & Brand

Produk: 82 • International brands: 1
Produk
  • Injectable Rocuronium Bromide
    Solution • 10 mg / mL • Intravenous • Canada • Approved
  • Rocuronium
    Injection, solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Rocuronium
    Injection, solution • 100 mg/10mL • Intravenous • US • Generic • Approved
  • Rocuronium
    Injection, solution • 50 mg/5mL • Intravenous • US • Generic • Approved
  • Rocuronium
    Injection, solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Rocuronium
    Injection, solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Rocuronium
    Injection, solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Rocuronium
    Injection, solution • 10 mg/1mL • Intravenous • US • Generic • Approved
Menampilkan 8 dari 82 produk.
International Brands
  • Esmeron

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul